National Drugs Strategy: progress in 2015
by Lucy Dillon
The Department of Health has published its annual report for 2015 on progress in implementing the actions included in the National Drugs Strategy.The report is a descriptive account of activities over the period – in some cases they are reported at a national level, while in others they are reported at the level of the Community Healthcare Organisations (CHOs).
read more »
|
After UNGASS 2016
UNGASS 2016 has been and gone. Held on 19–21 April in New York, it comprised not only the general assembly sessions but also over 40 side events, which were organised by individual member states, UN agencies and international NGOs.
read more »
|
Drug users’ human rights
Just what are the rights of drug users and how can legislators, policy makers, law enforcers and service providers ensure their rights are taken into consideration? In 2015 the Irish Council for Civil Liberties (ICCL) produced its first paper considering the drugs phenomenon from a human rights perspective, and in particular human rights as defined in the European Convention on Human Rights (ECHR)
read more »
|
What are human rights?
According to the Irish Human Rights and Equality Commission (IHREC), ‘human rights are the basic rights and freedoms that belong to everyone. International law, including treaties, contain the provisions which give human rights legal effect.’1 In the decades since World War Two, human rights standards have been adopted at United Nations, Council of Europe and the European Union level. Ireland has committed to upholding many of these standards.
read more »
|
|
 |
European drug trends 2016
by Brian Galvin
In May 2016 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) published the European drug report 2016: trends and developments summarising the latest trends across the 28 EU member states, and Norway and Turkey.1 The report highlights the increasing use of MDMA following a period of decline in recent years, with greater levels of production helped by new sources of precursors and production techniques. The drug’s popularity with existing stimulant users has grown and a new generation of users is emerging, presenting greater health risks as more high potency products become available.
read more »
|
|
|